Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors
David H. Henry(Pennsylvania Hospital), Howard Yeh(Hospital de Santa Maria), Geoffrey Smith(Amgen (United States)), Roger von Moos(Kantonsspital Graubünden), Roger Dansey(Memorial Sloan Kettering Cancer Center), Vera Hirsh(Taipei Veterans General Hospital), Luís Costa(University of Lisbon), Giorgio V. Scagliotti(Ospedale San Luigi Gonzaga), Vânia Hungria(Faculdade de Ciências Médicas da Santa Casa de São Paulo), Susie Jun(Ellis Hospital), Penella J. Woll(University of Sheffield), Amy Feng(Amgen (United States)), Saroj Vadhan‐Raj(The University of Texas MD Anderson Cancer Center)
Cited by 182
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
|Journal of Clinical Oncology|2004|1.7k